Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Induction Chemotherapy for Larynx Preservation
NCT06554028Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in laryngeal cancer, hypopharyngeal cancer, sponsored by Henan Cancer Hospital. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
laryngeal cancerhypopharyngeal cancer
Beyond the preview
Go deeper on NCT06554028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06554028.